Eighteen-year-old Matteo Paz has stunned the scientific community by using AI and machine learning to identify 1.5 million ...

(Photo submitted) Call Andy Hallman at 641-575-0135 or email him at [email protected] Three Maharishi School students earned a "boarding pass" to the Regeneron International Science ...

Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $150 from $170 and keeps a Hold rating on the shares. The ...

FDA accepts Regeneron's sBLA for Eylea HD in RVO with priority review; QUASAR data supports monthly dosing, target action date set for August 2025.

The stock's fall snapped a two-day winning streak.

Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face ...

BENGALURU: Biopharmaceutical company Biocon's share price on Tuesday jumped over 4 per cent after its subsidiary Biocon ...

This agreement enables the company to launch in the US in the second half of calendar year 2026 or earlier in certain circumstances ...

In a report released on April 11, Salveen Richter from Goldman Sachs maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $917.00. The company’s shares closed ...

Biocon Biologics on Tuesday said it has inked a settlement and licensing pact with Regeneron, paving the way to commercialise its biosimilar product Yesafili in the US.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection ...